Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
Due to resistance and BCR-ABLT315I-mutated, CML remains a clinical challenge. It needs new potential therapeutic targets to overcome CML resistance related to BCR-ABL. Our research revealed that the deubiquitinating enzyme USP28 was highly expressed in BCR-ABL-dependent CML patients. Similarly, a hi...
Main Authors: | Zilin Li, Yiling Xi, Linglan Tu, Xu Zhang, Yue Huang, Huizong Nie, Cheng Peng, Haohuan Chai, Shenxin Zeng, Xiaoliang Zheng, Liyan Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332224001963 |
Similar Items
-
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01) -
Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01) -
Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: M Yaghmaie, et al.
Published: (2005-09-01) -
Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: Yaghmaie M., et al.
Published: (2005-09-01) -
Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain
by: Maysaa A. Dhahii
Published: (2010-04-01)